All In Biotech

NDA 212839 · Sk Life

Xcopri

Cenobamate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Aug 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 21, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

19

7 Phase 3, 3 recruiting

FAERS reports

8,531

3,375 serious, 208 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 25, 2025.

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. ( 1 )

Mechanism: The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown. Cenobamate has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABA A ) ion channel.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 21, 2019 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
6 products under this application
  • XCOPRI · CENOBAMATE 200MG · TABLET, ORAL · Prescription
  • XCOPRI · CENOBAMATE 100MG · TABLET, ORAL · Prescription
  • XCOPRI · CENOBAMATE 25MG · TABLET, ORAL · Prescription
  • XCOPRI · CENOBAMATE 150MG · TABLET, ORAL · Prescription
  • XCOPRI · CENOBAMATE 50MG · TABLET, ORAL · Prescription
  • XCOPRI · CENOBAMATE 12.5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cenobamate" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure2,543
  • product dose omission issue1,880
  • fatigue845
  • somnolence823
  • off label use691
  • dizziness668
  • product use issue608
  • fall470
  • headache391
  • wrong technique in product usage process382
  • drug ineffective380
  • drug interaction364

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20195
202084
20211,679
2022612
2023558
20241,527
20252,057
20262,009

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xcopri (Cenobamate)

2024 spending

$165M

Beneficiaries

12,500

117,028 claims

Per beneficiary

$13,176

$38.43 per unit

View as table
YearSpending
2020$3,577,855
2021$32,547,978
2022$68,154,842
2023$113,076,802
2024$164,703,013

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 52 on PubMed

Sponsor: Sk Life

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.